SAN FRANCISCO--(BUSINESS WIRE)--Siris Medical, Inc., a company with headquarters in Silicon Valley and Boston that offers the only Artificial Intelligence (AI)-driven treatment decision-support system for use in radiation oncology, announced today that it has been awarded a contract with Montefiore Medical Center. Montefiore will implement Siris's InsightRT™ software platform to offer Clinical Decision Support and provide insight into patient-specific treatment outcomes prior to initiating treatment.
"In my career, having more accurate insights into patient outcomes is key to so many decisions that we share with our patients. This innovation will be embraced by both caregivers and patients alike for its positive impact on patient care and the patient experience," said Marc Nash MD, Chief Medical Officer of Siris Medical.
"We're thrilled for this partnership with Montefiore Medical Center. With this added capability, Siris's platform will deliver, for the first time, an opportunity for clinicians to instantly match outcomes between new patients and historical patients, bringing new insights to shared decision making," adds Colin Carpenter PhD, President and CEO of Siris Medical.
About InsightRT
The QuickMatch module of InsightRT utilizes artificial intelligence and the rich experience of historical treatments to give clinicians insight into the best achievable treatment for each individual patient while eliminating the need for time consuming iterations that delay a patient's time to treatment. InsightRT is the only AI-driven radiotherapy treatment planning decision-support product on the market.
About Siris Medical
Siris Medical empowers clinicians to achieve efficient high-quality cancer radiation treatment decisions through its artificial intelligence platform, InsightRT, the first commercial decision-support system in radiation oncology.
